Overcoming the Challenges for Early Stage Life Sciences Companies: The Interface Biologics Story
All early stage life sciences companies face similar challenges, among these are 1) the balance of science vs. commercialization, 2) management of Intellectual Property, 3) effective recruitment, and 4) ongoing financing. Tom Reeves, President and CEO of Interface Biologics, Inc. (IBI) will use the IBI story to illustrate one example of successfully navigating these troubled waters. Through a description of IBI’s technology foundation, financing history, commercialization success and exit strategy, Tom will share his thoughts on what it takes to survive and thrive in the difficult environment that is inherent in early stage companies.
Tom Reeves is President and Chief Executive Officer of Interface Biologics (IBI) – a privately held commercial stage company that develops transformative bio-medical polymer technology to improve the safety and effectiveness of a broad range of medical devices. Prior to IBI, Tom was President and Chief Operating Office of Occulogix, Inc. a publicly traded medical device company focused on treatments for age-related eye diseases. He was instrumental in the company’s 2004 IPO which raised $100M on a $500M valuation. Prior to OccuLogix, Tom was President and CEO of Borderfree, Ltd. a venture-backed international e-commerce service provider which was sold to Canada Post. Tom also spent 14 years in the computer products industry managing wholesale distribution companies in Canada, Europe and the UK. He began his career at the Boston Consulting Group in San Francisco and has degrees in economics and international relations from Harvard University and the Australian National University.